Posts

Posted on

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News and Presentations section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. Relay Therapeutics’ Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:

Pete Rahmer
Chief Corporate Development Officer
617-322-0715
[email protected]

Media:
Dan Budwick
1AB
973-271-6085
[email protected]



Posted on

Watsco Declares $1.95 Quarterly Dividend 48th Consecutive Year of Paying Dividends

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $1.95 on each outstanding share of its Common and Class B common stock payable on January 31, 2022 to shareholders of record at the close of business on January 14, 2022.

Watsco has paid dividends for 48 consecutive years. The Company’s philosophy is to share increasing amounts of cash flow with shareholders through higher dividends while maintaining a conservative financial position. Future dividends will be considered in light of investment opportunities, cash flow, general economic conditions and the Company’s financial condition.

About Watsco

Watsco is the largest distribution network for heating, air conditioning and refrigeration (HVAC/R) products with locations in the United States, Canada, Mexico and Puerto Rico, and on an export basis to Latin America and the Caribbean. Watsco estimates that over 350,000 contractors and technicians visit or call one of its 673 locations each year to get information, obtain technical support and buy products.

The Company believes there is long-term opportunity to be a significant participant and contributor in efforts to address climate change. HVAC/R products provide comfort to homes and businesses regardless of the outdoor climate. Older systems often operate below current government-mandated energy efficiency and environmental standards, resulting in higher energy use and costs to homeowners. Sales of higher-efficiency replacement systems have long been a fundamental opportunity in Watsco’s marketplace. Watsco plans to actively collaborate with its OEM partners and key stakeholders to lead these ongoing efforts in its marketplace. Additional information about Watsco may be found at www.watsco.com.

This document includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our expected financial and operational results and the related assumptions underlying our expected results. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive market, new housing starts and completions, capital spending in commercial construction, consumer spending and debt levels, regulatory and other factors, including, without limitation, the effects of supplier concentration, competitive conditions within Watsco’s industry, the seasonality of product sales, the ability of the Company to expand its business, insurance coverage risks and final GAAP adjustments. Detailed information about these factors and additional important factors can be found in the documents that Watsco files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were made. Watsco assumes no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as required by applicable law.

Barry S. Logan
 

Executive Vice President

(305) 714-4102

e-mail: blogan @watsco.com



Posted on

PolyPid Announces Planned CEO Transition

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022

PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company’s Executive Vice President and Chief Financial Officer, as PolyPid’s Chief Executive Officer, effective July 1, 2022. Amir Weisberg, who currently serves as Chief Executive Officer and a director, will direct a transition period with Ms. Czaczkes Akselbrad beginning on April 1, 2022, and will retire from the Chief Executive Officer position, a role in which he has served for over 11 years, effective on July 1, 2022.

“On behalf of the Board of Directors, I would like to congratulate Dikla on her well-deserved appointment as CEO,” said Jacob Harel, PolyPid’s Chairman. “Since joining PolyPid seven years ago, she has been instrumental in guiding our financial, strategic and operational objectives. As we approach commercialization, our business is at a critical inflection point, and we are confident that under Dikla’s leadership, we will execute on the many compelling opportunities that lie ahead of us. Moreover, we will continue to benefit from Amir’s invaluable strategic support over the coming months. Under his leadership, PolyPid is in the strongest operational and financial position in its history, and we thank Amir for his significant contributions as CEO over the past 11 years.”

“It has been an honor to have served as CEO of PolyPid throughout the development phase of our company,” stated Mr. Weisberg. “As we prepare for our next phase of growth, Dikla is the ideal future leader of the Company. It has been a privilege working alongside her over the past several years. Dikla brings a relentless focus on operational execution, and a proven track record of driving growth and innovation. I look forward to continuing to work closely with her as we further advance our business in the coming quarters.”

“I am grateful to have the opportunity to lead the Company at this exciting time in our corporate evolution,” said Ms. Czaczkes Akselbrad. “We continue to rapidly advance our many development programs, including the large Phase 3 program for our lead asset, D-PLEX100, for the prevention of Surgical Site Infections, as well as progress our commercial preparations. In addition, our promising OncoPLEX development platform initially targeting brain tumors continues to generate compelling preclinical data, and we are preparing to begin a clinical study this year. I look forward to continuing to work with our talented and passionate team to achieve further clinical and operational success and drive long-term shareholder value.”

Separately, PolyPid announced that Shaul Mukhtar, Ph.D., Chief Operating Officer of PolyPid, will be retiring from the Company, effective March 2022, following two and a half years with PolyPid.

Ms. Czaczkes Akselbrad is an experienced life sciences industry executive who has demonstrated the ability to lead a company through critical international strategic, financial and business transitions, including raising over $300 million in various forms in her last two positions. She has more than 20 years of experience in strategic planning, managing corporate teams, establishing international company procedures and standards, and driving major corporate negotiations with global companies. Prior to joining PolyPid as the Chief Financial Officer in 2014, Ms. Czaczkes Akselbrad served as Chief Financial Officer of Compugen Ltd. (NASDAQ & TASE: CGEN), a leading biotechnology company focused on the discovery and licensing of product candidates to the drug industry. She received a B.A. in accounting and economics from Tel-Aviv University, and an MBA from Tel-Aviv University.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).

For additional company information, please visit polypid.com and follow us on Twitter and LinkedIn.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of many compelling opportunities, the rapid advancement of the Company’s development programs, including the large Phase 3 program for D-PLEX100, as well as progress of its commercial preparations, the Company’s OncoPLEX development platform and preparations to begin a clinical trial this year, and achievement of further clinical and operational success and long-term shareholder value. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact:

PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investor Contact:

Bob Yedid
LifeSci Advisors
646-597-6989
[email protected]

Media Contact:

Nechama Feuerstein
551-444-0784
[email protected] 



Posted on

CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it has launched an initial public offering of 11,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission. The initial public offering price is expected to be between $15 and $17 per share. All shares of common stock to be sold in the proposed offering will be offered by CinCor. CinCor also intends to grant the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. CinCor’s common stock is expected to begin trading on the Nasdaq Global Market under the symbol “CINC.”

Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms of the proposed offering.

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective.

The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained by contacting may be obtained from: Morgan Stanley & Co. LLC by mail at Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at (866) 718-1649 or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CinCor

CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.

Forward-Looking Statements 
This press release contains certain forward-looking statements, including, but not limited to, statements with regard to CinCor’s proposed initial public offering. Words such as “anticipates,” “believes,” “expected,” “proposed,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed securities offering and the terms thereof are subject to numerous factors, many of which are beyond the control of CinCor, including, without limitation, market conditions and the risk factors and other matters set forth in CinCor’s registration statement on Form S-1 and the preliminary prospectus included therein and the other filings CinCor makes with the Securities and Exchange Commission. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts:

Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO

Investors:
Bob Yedid
LifeSci Advisors
[email protected] 



Posted on

One of World’s Largest MNOs to Deploy Gilat’s 4G Cellular Backhaul over Satellite Technology

Gilat will enable the MNO to provide Voice and Data over LTE to its subscribers, with deployment expected in first quarter of 2022

PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that one of the world’s largest Mobile Network Operators (MNOs) will deploy 4G cellular backhaul over satellite technology from Gilat.

The top-tier MNO, serving hundreds of millions of subscribers in Asia, will implement Gilat’s SkyEdge II-c system and Capricorn Outdoor VSATs, which will enable improved Voice and Data over LTE services for its mobile subscribers. This 4G cellular backhaul solution over satellite is expected to be deployed in the first quarter of 2022.

“This new deal represents a major market penetration achievement with significant upside potential for Gilat,” said Michal Aharonov, Chief Commercial Officer at Gilat. “Already proven worldwide with market adoption of about 80%, our industry-leading 4G cellular backhaul over satellite solution was selected because of its superior technology and proven track record. We expect to see an expansion of business with this top-tier MNO, and other MNOs throughout the world, as we move forward into 2022.”

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With 30 years of experience, we design and manufacture cutting-edge ground segment equipment, and provide comprehensive solutions and end-to-end services, powered by our innovative technology. Delivering high value competitive solutions, our portfolio comprises of a cloud based VSAT network platform, high-speed modems, high performance on-the-move antennas and high efficiency, high power Solid State Amplifiers (SSPA) and Block Upconverters (BUC).

Gilat’s comprehensive solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense and public safety, all while meeting the most stringent service level requirements. Gilat controlling shareholders are the FIMI Private Equity Funds. For more information, please visit: www.gilat.com

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, risks associated with the outbreak and global spread of the coronavirus (COVID-19) pandemic; changes in general economic and business conditions, inability to maintain market acceptance to Gilat’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology and risks associated with Gilat’s international operations and its location in Israel. For additional information regarding these and other risks and uncertainties associated with Gilat’s business, reference is made to Gilat’s reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

Contact:

Gilat Satellite Networks
Doreet Oren, Senior Director Corporate Communications
[email protected]

GK Investor and Public Relations
Ehud Helft, Managing Partner
[email protected]



Posted on

NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use

– Invention by NRx scientists provides a path to long-term patent protection for ZYESAMI® (aviptadil)

– Compositions focus on buffer-free formulations with long-term shelf stability

– NRx is changing prior guidance to investors regarding the possibility of “Orange Book” protection upon FDA New Drug Approval

PR Newswire

RADNOR, Pa., Jan. 3, 2022 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled “Stable, Buffer-free Compositions of Vasoactive Intestinal Peptide (VIP).” The provisional application describes compositions of vasoactive intestinal peptide, the synthetic form of which is aviptadil, that are both shelf stable and biologically active when used to treat COVID-19 and other diseases.

There have been previous attempts to create stable forms of aviptadil for pharmaceutical use that include the use of various additives, such as buffers, mannitol, and sucrose. Those additives routinely compensate for lack of strict chemical controls in drug formulations. However, NRx was advised in late 2020 that such formulations lead to inactivation of the peptide and cannot be used in human treatment.

The current invention relies on specific approaches to controlling the chemical environment of VIP, an extremely delicate peptide, in order to maintain its stability without the use of such additives. The project was led by an industry-veteran development team that collectively has more than two centuries of drug formulation and development experience.

Prior to this invention, VIP could only be manufactured for human use in small batches with a shelf-life that expired after several weeks. The invention is significant to NRx’s drug development efforts because it provides a path to long-term shelf stability and a drug that can be included in national stockpiles. The patent filing also provides a path to inclusion in the FDA “orange book” of innovative drugs. Medicines that lack an orange book listing may be offered for sale by generic drug manufacturers after a statutory period that ranges from three to seven years. Orange book listed medicines, on the other hand, may not be offered for sale by generic manufacturers for the life of the patent.

The inventions identified in the recently-filed patent have already been incorporated into the manufacture of ZYESAMI® (aviptadil) and were reviewed by the FDA as part of its review of ZYESAMI’s manufacturing process in September 2021. NRx anticipates that upon regulatory approval should safety and efficacy be demonstrated, ZYESAMI now has a path to drug release and innovative drug protection in the marketplace.

“In our previous guidance to investors, we advised that there were no filed patents protecting the manufacture of ZYESAMI. With the filing of this patent and the inventions described within, we at NRx believe we have a path to a long term commercial life for a stable and pharmaceutically active form of VIP as an innovative drug,” said Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “Although, for obvious reasons, our initial focus has been the use of VIP in lung disease caused by COVID-19, we are now considering potential use of ZYESAMI in non COVID-related lung disease, liver disease, eye disease, and organ transplantation. We are deeply grateful to our partners at Nephron Pharmaceuticals for working with us and embracing the painstaking work required to bring a seventy-year-old dormant drug to life.”

About NRx Pharmaceuticals

NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.

NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. NRx is chaired by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in six biotechnology startup companies with public exits and been appointed to advisory roles in four US Presidential Administrations. The NRx board includes Dr. Sherry Glied, former US Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the US FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.) the 26th United States National Security Advisor.

About ZYESAMI® (aviptadil)

Aviptadil is a synthetic form of Vasoactive Intestinal Polypeptide (VIP) first discovered by the late Prof. Sami Said in 1970, and ZYESAMI® is named in his honor. Although primarily concentrated in the lung, it was first purified from the intestinal tract. VIP binds specifically to the alveolar type II cell (ATII) in the air sac (alveolus) of the lung, where it has been shown have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, VIP stimulates ATII cells to make the surfactant that must coat the lining of the lungs in order for them to exchange oxygen with the blood.  Loss of surfactant causes respiratory failure and alveolar collapse, which are hallmarks of COVID-19.

COVID-19-related respiratory failure is caused by selective infection of the ATII cell by the SARS-CoV-2 virus. The ATII cells are vulnerable because of their (ACE2) surface receptors, which serve as the route of entry for the virus. Coronavirus infection of the ATII cell shuts down surfactant production, triggers the formation of inflammatory cytokines, and causes cell death (cytopathy). VIP is shown to upregulate surfactant production, block Coronavirus replication in the ATII cell, block cytokine synthesis, and prevent viral-induced cell death (cytopathy). Other than ZYESAMI®, no currently proposed treatments for COVID-19 specifically target this mechanism of action.

Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the company’s management.  

The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

MEDIA CONTACT:
Jack Hirschfield
Head of Corporate Communications, NRx
[email protected] 

INVESTOR RELATIONS
Eric Goldstein
LifeSci Advisors
[email protected] 
646-791-9729

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-files-provisional-patent-for-stable-compositions-of-aviptadil-suitable-for-human-use-301452657.html

SOURCE NRx Pharmaceuticals

Posted on

Velodyne Lidar to Participate in the 24th Annual Needham Virtual Growth Conference

Velodyne Lidar to Participate in the 24th Annual Needham Virtual Growth Conference

SAN JOSE, Calif.–(BUSINESS WIRE)–
Velodyne Lidar, Inc. (NASDAQ: VLDR, VLDRW), the leading lidar company, known worldwide for its broad portfolio of breakthrough lidar technologies, announces participation in the upcoming 24th Annual Needham Virtual Growth Conference being held January 10-14, 2022.

Management will present on Thursday, January 13, 2022, at 2:00 p.m. ET. A live and archived audio webcast of the presentation will be accessible on the company’s investor relations website at investors.velodynelidar.com.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Investor Contact:

Andrew Chan

Head of Investor Relations

[email protected]

Media

Liv Allen

(415) 370-0716

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Transport Audio/Video Transport Other Technology Technology

MEDIA:

Logo
Logo
Posted on

Universal Electronics Inc. to Present at the 24th Annual Needham Virtual Growth Conference on January 13th

Universal Electronics Inc. to Present at the 24th Annual Needham Virtual Growth Conference on January 13th

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices, announced that Paul Arling, Chairman and Chief Executive Officer and Bryan Hackworth, Chief Financial Officer, are scheduled to attend the 24th Annual Needham Virtual Growth Conference being held January 10-14, 2022.

Management will present at 4:15 p.m. ET on Thursday, January 13, 2022, and host one-on-one meetings over the course of January 11-13, 2022. A webcast of the presentation will be available live and via replay for a period of 90 days at www.uei.com.

About Universal Electronics Inc.

Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in wireless universal control solutions for home entertainment and smart home devices. We design, develop, manufacture, ship and support control and sensor technology solutions and a broad line of universal control systems, audio video accessories, and intelligent wireless security and smart home products. Our products and solutions are used by the world’s leading brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. For more information, visit www.uei.com.

Press

Paul Arling

Chairman & CEO

Universal Electronics Inc.

+1 480-530-3000

[email protected]

Investor

Kirsten Chapman

Managing Director

LHA Investor Relations

[email protected]

+1 415-433-3777

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Technology Audio/Video Consumer Electronics

MEDIA:

Logo
Logo
Posted on

U-Haul Growth Index: Texas is the No. 1 Growth State of 2021

Texas edged Florida for the largest net gain of one-way U-Haul trucks in 2021; California and Illinois saw the greatest net losses

PR Newswire

PHOENIX, Jan. 3, 2022 /PRNewswire/ — Migration to southern states continues to be magnified by the lingering pandemic, and no state netted more U-Haul® customers during the last year than Texas.

The Lone Star State earned bragging rights as the leading growth state of 2021, narrowly besting Florida for tops honors, according to transactional data compiled for the annual U-Haul Growth Index.

Tennessee ranks third, South Carolina fourth and Arizona fifth among the top growth states.

Growth states are calculated by the net gain of one-way U-Haul trucks entering a state versus leaving that state in a calendar year. Migration trends data is compiled from well over 2 million one-way U-Haul truck customer transactions that occur annually.

California is 50th and Illinois 49th on the list for the second consecutive year, indicating those states once again witnessed the largest net losses of one-way U-Haul trucks.

Texas reclaims the No. 1 growth state status it held from 2016-18. It ranked second to Florida in 2019 and Tennessee in 2020.

“We see a lot of growth coming from the East and West Coast,” said Matt Merrill, U-Haul Area District Vice President of the Dallas Fort-Worth Metroplex and West Texas. “A lot of people moving here from California (and) New York. We also see a lot of people coming in from the Chicago markets. I think that’s a lot due to the job growth – a lot of opportunity here. The cost of living here is much lower than those areas. Texas is open for business.”

Indiana, Colorado, Maine, Idaho and New Mexico round out the top 10 growth states of 2021 as self-movers target the Southeast, Southwest and Rocky Mountain regions as their destinations of choice.

Select Northeast markets showed year-over-year migration recoveries as Maine rose 21 spots, Vermont 14 spots and Connecticut 25 spots in the U-Haul Growth Index. Yet three of the six states with the largest net losses were also in the Northeast: New York (45), Massachusetts (47) and Pennsylvania (48).

California remained the top state for out-migration, but its net loss of U-Haul trucks wasn’t as severe as in 2020. That can be partially attributed to the fact that U-Haul simply ran out of inventory to meet customer demand for outbound equipment.

Texas’s growth is statewide, although some of its biggest gains occurred in the suburbs around the DFW Metroplex. Florida’s gains are equally widespread, with considerable growth south of Orlando and along both coastlines.

Overall moving traffic across Texas increased in 2021, as it did in most states. Arrivals of one-way U-Haul trucks jumped 19% while departures rose 18% over 2020. Arrivals made up 50.2% of all one-way U-Haul traffic last year in Texas.

“The Texas economy is growing fast,” stated Kristina Ramos, U-Haul Company of South Austin president. “With a strong job market and low cost of living, it’s a no brainer. Texas doesn’t have an income tax, so families get more for their money.”

Visit myuhaulstory.com to view the top 25 U.S. growth cities, individual state reports and the top 25 Canadian growth cities.

While U-Haul migration trends do not correlate directly to population or economic growth, the U-Haul Growth Index is an effective gauge of how well cities are both attracting and maintaining residents.


2021 U-HAUL GROWTH STATES


1.

TEXAS (2)


2.

FLORIDA (3)


3.

TENNESSEE (1)


4.

SOUTH CAROLINA (15)


5.

ARIZONA (5)


6.

INDIANA (12)


7.

COLORADO (6)


8.

MAINE (29)


9.

IDAHO (30)


10.

NEW MEXICO (39)


11.

SOUTH DAKOTA (25)


12.

VERMONT (26)


13.

WISCONSIN (13)


14.

OREGON (45)


15.

WASHINGTON (36)


16.

ALASKA (34)


17.

MINNESOTA (20)


18.

CONNECTICUT (43)


19.

NORTH CAROLINA (9)


20.

NEBRASKA (32)


21.

WYOMING (33)


22.

MONTANA (19)


23.

GEORGIA (10)


24.

OHIO (4)


25.

NEW HAMPSHIRE (23)


26.

WEST VIRGINIA (16)


27.

IOWA (24)


28.

UTAH (17)


29.

NEVADA (8)


30.

DELAWARE (27)


31.

VIRGINIA (28)


32.

RHODE ISLAND (35)


33.

NORTH DAKOTA (37)


34.

MARYLAND (46)


35.

WASHINGTON, D.C. (38)*


36.

NEW JERSEY (48)


37.

MISSISSIPPI (31)


38.

KENTUCKY (18)


39.

MISSOURI (7)


40.

KANSAS (21)


41.

ARKANSAS (11)


42.

MICHIGAN (40)


43.

LOUISIANA (44)


44.

OKLAHOMA (14)


45.

NEW YORK (42)


46.

ALABAMA (22)


47.

MASSACHUSETTS (47)


48.

PENNSYLVANIA (41)


49.

ILLINOIS (49)


50.

CALIFORNIA (50)


2020 growth rankings in parentheses

 


* Washington, D.C. is its own U-Haul market and
is listed among growth states for migration trends
purposes. Hawaii is excluded since state-to-state
U-Haul truck moves do not occur.

U-Haul is the authority on migration trends thanks to its expansive network that blankets all 10 provinces and 50 states. The geographical coverage from more than 23,000 U-Haul truck- and trailer-sharing locations provides a comprehensive overview of where people are moving like no one else in the industry. Find U-Haul stores and neighborhood dealers at uhaul.com/locations.

Independent small business owners interested in joining the U-Haul Dealer Network at no cost and earning commissions from rental transactions at their locations can visit uhaul.com/dealer to learn more and submit an information form.

Increased demand for Moving Help® through movinghelp.com has mirrored increased demand for one-way U-Haul equipment during the pandemic. Moving Help has been the No. 1 choice of customers seeking labor services for loading and unloading during their moves since 2002, offering a network of 6,700 local and independent Moving Help Service Providers across all 50 states and 10 Canadian provinces. With more than 5 million jobs completed and 2.3 million customer reviews, customers have access to the largest network of moving labor services in North America through Moving Help.

About U-HAUL

Since 1945, U-Haul has been the No. 1 choice of do-it-yourself movers, with a network of more than 23,000 locations across all 50 states and 10 Canadian provinces. U-Haul Truck Share 24/7 offers secure access to U-Haul trucks every hour of every day through the customer dispatch option on their smartphones and our proprietary Live Verify technology. Our customers’ patronage has enabled the U-Haul fleet to grow to approximately 176,000 trucks, 126,000 trailers and 46,000 towing devices. U-Haul offers nearly 825,000 rentable storage units and 71.6 million square feet of self-storage space at owned and managed facilities throughout North America. U-Haul is the largest retailer of propane in the U.S., and continues to be the largest installer of permanent trailer hitches in the automotive aftermarket industry. U-Haul has been recognized repeatedly as a leading “Best for Vets” employer and was recently named one of the 15 Healthiest Workplaces in America.

Contact:

Jeff Lockridge

Sebastien Reyes

E-mail: [email protected]
Phone: 602-760-4941
Website: uhaul.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/u-haul-growth-index-texas-is-the-no-1-growth-state-of-2021-301452567.html

SOURCE U-Haul

Posted on

CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE

PR Newswire

ROCKVILLE, Md. and BEIJING, Jan. 3, 2022 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that on December 30, 2021, CASI received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying CASI that, for the previous 30 consecutive business days, the bid price of CASI’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

The Nasdaq deficiency letter has no immediate effect on the listing of CASI’s common stock on the Nasdaq Capital Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), CASI has been provided an initial period of 180 calendar days, or until June 28, 2022 (the “Compliance Date”), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for CASI’s common stock closes at $1.00 or more per share for a minimum of 10 consecutive business days, as required under the Compliance Period Rule, the Staff will provide written notification to CASI that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).

If CASI does not regain compliance with the Bid Price Rule by the Compliance Date, CASI may be eligible for an additional 180 calendar day compliance period (the “Second Compliance Period”). To qualify, CASI would need to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Bid Price Rule, and provide written notice to the Staff of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary.

However, if CASI does not regain compliance with the Bid Price Rule by the Compliance Date and it appears to the Staff that CASI will not be able to regain compliance with the Bid Price Rule during the Second Compliance Period, or CASI is otherwise not eligible for the Second Compliance Period, then Nasdaq will provide notice to CASI that CASI’s common stock will be subject to delisting. At that time, CASI may appeal the Staff’s delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”). CASI expects that its common stock would remain listed pending the Panel’s decision. There can be no assurance that, if CASI does appeal the Staff’s delisting determination to the Panel, such appeal would be successful.

CASI intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and will consider available options, including a reverse stock split. In order to make available the option of a reverse stock split, CASI may submit a reverse stock split proposal to its stockholders at a special meeting of stockholders or its next annual meeting of stockholders. However, there can be no assurance that the reverse stock split will be approved or that CASI will be able to regain compliance with the Bid Price Rule.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, revenue growth, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors.


COMPANY CONTACT:

CASI Pharmaceuticals, Inc.

240.864.2643



[email protected]


INVESTOR CONTACT:

Bob Ai

Solebury Trout

646-389-6658


[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-receives-nasdaq-deficiency-notice-301452556.html

SOURCE CASI Pharmaceuticals, Inc.